Center for Vaccine Innovation and Access, PATH, Washington, DC, United States.
Front Immunol. 2023 Mar 2;14:1125102. doi: 10.3389/fimmu.2023.1125102. eCollection 2023.
Oral immunization is an effective strategy for inducing protective immunity against mucosal enteric pathogens. Although live-attenuated as well as subunit approaches have been explored for vaccination against enteric pathogens, inactivated whole bacterial cells may also be effective in introducing protective immunity. Successfully accomplishing this goal with inactivated whole bacterial cells will require that a complex antigenic repertoire be presented in controlled immunogenic amounts, in a safe and relatively simple and self-contained delivery format. The benefit from immunization with whole cell vaccines can be further enhanced through genetic engineering to over-express selected antigens and also by the use of mucosal adjuvants to direct a more robust immunologic response. These steps are being taken for the development of ETVAX, the most clinically advanced vaccine candidate against the major enteric pathogen, enterotoxigenic (ETEC) with significant positive impact.
口服免疫是诱导针对肠道病原体的保护性免疫的有效策略。尽管针对肠道病原体的疫苗已经探索了减毒活疫苗和亚单位疫苗两种方法,但灭活全菌细胞也可能有效诱导保护性免疫。要成功实现这一目标,需要以安全、相对简单和自包含的方式,以受控的免疫原性剂量呈现复杂的抗原谱。通过基因工程过表达选定抗原,以及使用黏膜佐剂来引导更强大的免疫反应,可进一步增强全细胞疫苗免疫的益处。这些步骤正在为 ETVAX 的开发而采取,ETVAX 是针对主要肠道病原体肠毒性(ETEC)的最先进的临床候选疫苗,具有重要的积极影响。